- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06294353
Study of Efficacy and Safety of WELT-ED for Eating Disorder (WCTP-ED-B-01)
A Randomized, Multicenter, Treatment-as-usual Controlled Clinical Trial to Evaluate the Safety and Efficacy of Digital Cognitive Behavioral Therapy for Eating Disorder
The purpose of this clinical trial is to evaluate the safety and efficacy of a digital therapeutic device (WELT-ED) based on Cognitive Behavioral Therapy (CBT) for the treatment of eating disorders.
The main questions it aims to answer are:
- Is WELT-ED as effective as standard treatment in reducing the symptoms of eating disorders?
- Is the WELT-ED safe for use in the target population without causing adverse effects?
Participants will:
- Undergo assessments to determine their baseline health status and severity of eating disorder symptoms.
- Use WELT-ED or receive standard treatment as directed for the duration of the study period (8 weeks).
- Participate in assessments to monitor changes in their eating disorder symptoms and any potential side effects.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Yujin Lee
- Phone Number: 82-2-6439-0707
- Email: info@weltcorp.com
Study Locations
-
-
-
Seoul, Korea, Republic of, 03080
- Recruiting
- Seoul National University Hospital
-
Contact:
- soohee Choi
- Phone Number: 0215885700
- Email: soohchoi@snu.ac.kr
-
Seoul, Korea, Republic of, 03722
- Recruiting
- Severance Hospital
-
Contact:
- Young Chul Jung, MD
- Phone Number: 82-2-2228-1622
- Email: eugenejung@yuhs.ac
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adults aged between 19 and 65 years
- Diagnosed with an eating disorder according to ICD-10.
F50.0 Anorexia nervosa F50.1 Atypical anorexia nervosa F50.2 Bulimia nervosa F50.3 Atypical bulimia nervosa F50.4 Overeating associated with other psychological disturbances F50.5 Vomiting associated with other psychological disturbances F50.8 Other eating disorders F50.9 Eating disorder, unspecified)
- Have a binge eating frequency (as per item 14 of the EDE-Q) of 4 or more times over the past 4 weeks (28 days) at the time of screening.
- Able to use a mobile application (app) on a smartphone without difficulty.
- After receiving and understanding sufficient information about this clinical trial, voluntarily decides to participate and provides written consent.
Exclusion Criteria:
- Previously received Cognitive Behavioral Therapy for the treatment of an eating disorder.
- Have a history of bariatric surgery (e.g., adjustable gastric band, sleeve gastrectomy, biliopancreatic diversion, Roux-en-Y gastric bypass).
- Have a BMI less than 17 kg/m^2 or more than 40 kg/m^2 at the time of screening.
- Diagnosed with a major psychiatric disorder according to the MINI.
- Have a past or current diagnosis of schizophrenia or bipolar disorder.
- At risk of suicide (C-SSRS score of 4 or higher) or have attempted suicide in the past 2 weeks.
- Have active and progressive physical illnesses (e.g., congestive heart failure, chronic obstructive pulmonary disease, acute pain), neurological disorders (e.g., cerebrovascular disease), neurodegenerative diseases (e.g., dementia, multiple sclerosis), unstable medical conditions, or a life expectancy of less than 6 months.
- Pregnant or planning to become pregnant during the trial period.
- Participated in another clinical trial within 4 weeks prior to screening.
- Have a history of alcohol or substance abuse.
- Considered by the investigator to be unsuitable for participation in this clinical trial for any other reason.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: WELT-ED (CBT based DTx)
Participants in this group will receive a shortened version of the standard treatment plus access to the DTx app for 8 weeks. The DTx app is designed to provide therapeutic interventions based on CBT principles, aiming to help participants manage and reduce their eating disorder symptoms. Participants are expected to engage with the app, completing tasks such as self-monitoring food diaries. The app will collect data on adherence, including diary completion rates and app login frequency. Additional Support: Aside from app usage, participants will receive counseling and support therapy during visits at baseline, the 4-week mark, and the 8-week mark. They will continue any pre-existing medication for eating disorders. |
The product delivers Cognitive Behavioral Therapy for Eating Disorders (CBT-ED) through a software interface (iOS and Android), designed to engage patients in a structured and interactive manner.
It operates by analyzing patterns in the patient's lifestyle and eating data, identifying problematic behaviors associated with their eating disorder.
Based on this analysis, the software sets daily learning objectives aimed at fostering positive cognitive and behavioral habits.
By providing tailored guidance and support, the product seeks to assist patients in making sustainable changes, ultimately contributing to the improvement of eating disorder symptoms.
This approach combines the principles of CBT-ED with the convenience and accessibility of digital technology, offering a personalized therapeutic experience to support patients in their recovery.
|
Other: Standard Treatment
Participants will receive the standard treatment protocol for eating disorders, which includes regular counseling and support therapy at all scheduled visits. This treatment is comprehensive and follows the conventional approach to managing eating disorders, without the use of the DTx app. Participants will continue any pre-existing medication for eating disorders. |
In the control group, from screening/baseline (Visit 1) to 8 weeks (Visit 5), counseling and support therapy will be conducted at all visits.
Participants can continue taking SSRI medications and other antipsychotic drugs that they were already taking for the treatment of eating disorders during the trial period.
However, the intake of any additional antipsychotic drugs, other than those already being taken (including SSRIs), is prohibited during the trial period.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Binge Eating Frequency
Time Frame: from baseline (pre-use) to the 8-week point.
|
Change of Binge Eating Frequency (item 14 of the Eating Disorder Examination Questionnaire, EDE-Q)
|
from baseline (pre-use) to the 8-week point.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Eating Disorder Examination Questionnaire (EDE-Q)
Time Frame: 8 weeks
|
28 items divided into four subscales: dietary restraint, concern with eating, concern with body shape, and concern with weight.
Excluding frequency questions, it assesses symptoms over the past 4 weeks on a 7-point scale from 0 to 6, where higher scores indicate more problematic eating behaviors and attitudes.
|
8 weeks
|
Clinical Impairment Assessment (CIA)
Time Frame: 8 weeks
|
Purpose: Evaluates the secondary impairment in three main areas (personal, social, and cognitive) related to eating disorders. Format: A brief self-report tool consisting of 16 items, scored on a 4-point scale from 0 (no impairment) to 3 (high impairment). Interpretation: Total score ranges from 0 to 48, higher scores indicate greater personal, social, and cognitive impairment due to eating disorders. |
8 weeks
|
Patient health questionnaire-9 (PHQ-9)
Time Frame: 8 weeks
|
Purpose: Assesses symptoms of depression based on the diagnostic criteria for major depressive disorder in DSM-IV, focusing on the past two weeks. Format: Comprises 9 questions related to mood, sleep changes, fatigue, appetite change, guilt, worthlessness, concentration difficulty, restlessness, and suicidal thoughts, scored from 0 (not at all) to 3 (nearly every day). Interpretation: Higher scores indicate more severe symptoms of depression. |
8 weeks
|
Generalized anxiety disorder 7-item scale (GAD-7)
Time Frame: 8 weeks
|
Purpose: A screening tool developed to identify symptoms of generalized anxiety disorder, evaluating the severity of related anxiety or worry. Format: Contains 7 items, with responses ranging from 0 (not at all) to 3 (nearly every day). Interpretation: Total scores range from 0 to 21, with higher scores indicating more severe anxiety symptoms and greater functional impairment. |
8 weeks
|
The EuroQol Visual Analogue Scale (EQ-VAS)
Time Frame: 8 weeks
|
Purpose: Measures the participant's overall health status as part of a quality of life questionnaire. Format: A visual analogue scale from 0 to 100. Interpretation: Higher scores represent better overall health status. |
8 weeks
|
Clinical Global Impression of Improvement (CGI-I)
Time Frame: 8 weeks
|
Purpose: Assesses the degree of improvement or worsening in a participant's overall health status at 4 weeks (Visit 3) and 8 weeks (Visit 5). Format: Rated on a 7-point scale, with lower scores indicating greater improvement. Interpretation: Designed to provide a description of change over time, emphasizing the clinician's perspective on patient progress. |
8 weeks
|
Clinical Global Impression of Severity (CGI-S)
Time Frame: 8 weeks
|
Purpose: Evaluates the overall severity of the participant's condition at baseline, 4 weeks (Visit 3), and 8 weeks (Visit 5). Format: A 7-point scale is used, with higher scores indicating greater disease severity. Interpretation: Aims to quantify the severity of the condition from a clinical standpoint, offering insight into the disorder's impact on the patient's life. |
8 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
BMI (Body Mass Index)
Time Frame: 8weeks
|
The change in BMI from baseline (pre-use) to after 8 weeks of using the medical device (Visit 5) is assessed.
BMI = weight (kg) / height (m)^2.
|
8weeks
|
Adherence (Compliance) to WELT-ED (applicable only to WELT-ED Group)
Time Frame: 8weeks
|
Adherence at the 8-week mark (Visit 5) is evaluated based on the completion rate of self-monitoring food diaries and the number of logins to the app (applicable only to the experimental group).
|
8weeks
|
WELT-ED App Usage Satisfaction (applicable only to WELT-ED Group)
Time Frame: 8 weeks
|
App usage satisfaction is assessed through a questionnaire at the 8-week mark (Visit 5) (applicable only to the experimental group).
|
8 weeks
|
App-Based Lifestyle and Eating Data (applicable only to WELT-ED Group)
Time Frame: 8weeks
|
The participants' lifestyle habits (Activity data is evaluated as change of number of steps) and eating data are evaluated through self-monitoring food diaries collected via the app.
|
8weeks
|
Change in Regular Meal Frequency (applicable only to WELT-ED Group)
Time Frame: 8 weeks
|
Changes in the frequency of meals are assessed through self-monitoring food diaries collected via the app
|
8 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- WCTP-ED-B-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Binge-Eating Disorder
-
University of North Carolina, Chapel HillThe Hilda & Preston Davis Foundation; Global Foundation for Eating DisordersCompletedEating Disorder | Binge-eating DisorderUnited States
-
ShireCompleted
-
Lindner Center of HOPEUniversity of CincinnatiCompleted
-
Sao Jose do Rio Preto Medical SchoolFundação de Amparo à Pesquisa do Estado de São PauloCompletedBinge-Eating Disorder | Eating Disorders | Eating Behavior | Eating Disorder | Binge Eating Disorder Associated With ObesityBrazil
-
Nova Scotia Health AuthorityCompletedBinge-Eating Disorder | Eating DisorderCanada
-
BioprojetRecruiting
-
Lindner Center of HOPEJazz PharmaceuticalsRecruiting
-
Idorsia Pharmaceuticals Ltd.Completed
-
University of ChicagoTakedaCompleted
Clinical Trials on WELT-ED (CBT based DTx)
-
University Health Network, TorontoCompletedEating Disorder | PostTraumatic Stress DisorderCanada
-
University of SheffieldNot yet recruitingMeasurement Reliability | Clinician Competence
-
Norwegian School of Sport SciencesUniversity of Tromso; The Norwegian Women´s Public Health AssociationCompletedBulimia Nervosa | Binge Eating DisorderNorway
-
Vanderbilt UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedHypertension | Blood Pressure | Hypertensive EmergencyUnited States
-
VA Connecticut Healthcare SystemCompletedDiabetic Peripheral Neuropathic PainUnited States
-
University Health Network, TorontoActive, not recruiting
-
St. Joseph's Healthcare HamiltonCompletedSocial Anxiety Disorder
-
University of CopenhagenUniversity of Exeter; The University of Western AustraliaCompletedDepression | Recurrent DepressionDenmark
-
Emory UniversityAlzheimer's AssociationCompleted
-
Karolinska InstitutetCompletedPost Traumatic Stress DisorderSweden